title: Clinical inquiries. How should we treat major depression combined with anxiety?
authors.affiliation: Valley Family Medicine Residency, Renton, WA, USA.
authors.forename: Bonnie
authors.initials: B
authors.lastname: Trotter
authors.forename: Gary
authors.initials: G
authors.lastname: Kelsberg
authors.forename: Leilani
authors.initials: L
authors.lastname: St Anna
authors.forename: Vincent
authors.initials: V
authors.lastname: Lo
mesh_terms: D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D015928:Cognitive Behavioral Therapy / Q000379:methods; D003131:Combined Modality Therapy; D003865:Major Depressive Disorder / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D005194:Family Practice; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008991:Monitoring, Physiologic / Q000379:methods; D011613:Psychotherapy / Q000379:methods; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D017367:Selective Serotonin Reuptake Inhibitors